EnteroMedics (NASDAQ:ETRM)

Top Analyst Upgrades and Downgrades: Anadarko, Apple, Charter Communications, FireEye, First Solar, Frontier Communications and More

Stocks were indicated marginally lower on Wednesday, after a slight disappointment from Apple earnings and ahead of the expected status quo rate decision from the Federal Reserve later in the ...
Read Full Story »
biotech word cloud

Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday

As the markets are continuing to heat up a few biotech and pharma companies made massive gains on Thursday. There is a very positive sentiment in the health care sector ...
Read Full Story »
????????????????

Five Analyst Stock Picks With 100% or More Implied Upside

Every investor dreams of catching lightning in a bottle and picking that incredible stock that doubles or triples. Sometimes it is a well-known name that does it, and sometimes it ...
Read Full Story »
76764023

Analysts Target 150% Upside in EnteroMedics Stock Price

EnteroMedics Inc. (NASDAQ: ETRM) may be a largely unknown microcap stock to most investors. The company is in the development stages of making medical devices using neuroblocking technology to treat ...
Read Full Story »
biotech

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

It is not unusual to see biotech and biohealth companies raise cash after good news. After all, these companies either need to raise lots of cash from the market to fund ...
Read Full Story »
Traders

Today’s Market Winners and Losers

These are Friday's market winners and losers. Biggest Winners Shares of LinkedIn Corp. (NYSE: LNKD) are up 19.01% to $147.67, on trading volume of 5.1 million shares. The company reported ...
Read Full Story »
Wall St Bull statue

12 Stocks Expected to Rise by 50% to 100% (or More) in 2013 (AMRN, CRZO, CNDO, EMKR, ETRM, EXAS, GALE, MX, OEDV, REGI, SPWR, SGYP)

It may seem hard to believe, but some stocks are expected to rise by 50%, 100%, or even more over the next year. Our own DJIA peak price target is ...
Read Full Story »